Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Page, Sandra ^a,b,e   Birerdinc, Aybike ^a,b   Estep, Michael ^b,c   Stepanova, Maria ^a,b   Afendy, Arian ^b,c   Petricoin, Emanuel ^a   Younossi, Zobair ^b,c   Chandhoke, Vikas ^a   Baranova, Ancha ^a,b,d  

^a GEORGE MASON UNIVERSITY   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

^d RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; CYTOKINE; FAS LIGAND; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN RECEPTOR SUBSTRATE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN SHC; S6 KINASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CYTOKINE PRODUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; KNOWLEDGE BASE; LIVER FIBROSIS; MALE; MOLECULAR BIOLOGY; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CHEMOKINE CCL2; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FATTY LIVER; FEMALE; HUMANS; KNOWLEDGE BASES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84873561455     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056009     Document Type: Article

References (20)

1. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, et al. (2010) Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 51: 111-120.
2. Sanchez-Carbayo M, (2011) Antibody microarrays as tools for biomarker discovery. Methods Mol Biol 785: 159-182.
3. Wilson B, Liotta LA, Petricoin E, (2010) Monitoring proteins and protein networks using reverse phase protein arrays. Dis Markers 28: 225-232.
4. Yilmaz Y, Kedrah AE, Ozdogan O, (2009) Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 15: 4387-4391.
5. Ochs MF, (2010) Knowledge-based data analysis comes of age. Brief Bioinform 11: 30-39.
6. Lazo M, Clark JM, (2008) The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28: 339-350.
7. Baranova A, Younossi ZM, (2008) The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology 47: 373-375.
8. Emanuele E, (2008) Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 48: 2086-2087.
9. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R, (2011) Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis 20: 153-159.
10. Baranova A, Lal P, Birerdinc A, Younossi ZM, (2011) Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 11: 91.
11. Baranova A, Randhawa M, Jarrar M, Younossi ZM, (2007) Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev Mol Diagn 7: 195-205.
12. Jarrar M, Baranova A, Collantes R, Ranard B, Stepanova M, et al. (2008) Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 27: 412-421.
13. Younossi ZM, Baranova A, Stepanova M, Page S, Calvert VS, et al. (2010) Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res 9: 3218-3224.
14. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, et al. (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174.
15. Panasiuk A, Wysocka J, Maciorkowska E, Panasiuk B, Prokopowicz D, et al. (2005) Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J Gastroenterol 11: 7661-7665.
16. Singhal S, Chakravarty A, Das BC, Kar P, (2009) Tumour necrosis factor-alpha and soluble Fas ligand as biomarkers in non-acetaminophen-induced acute liver failure. Biomarkers 14: 347-353.
17. Song le H, Binh VQ, Duy DN, Bock TC, Kremsner PG, et al. (2004) Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol 73: 244-249.
18. Szuster-Ciesielska A, Daniluk J, Bojarska-Junak A, (2005) Apoptosis of blood mononuclear cells in alcoholic liver cirrhosis. The influence of in vitro ethanol treatment and zinc supplementation. Toxicology 212: 124-134.
19. Tokar JL, Berg CL, (2002) Therapeutic Options in Nonalcoholic Fatty Liver Disease. Curr Treat Options Gastroenterol 5: 425-436.
20. Stephen S, Baranova A, Younossi ZM, (2012) Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol 6: 163-171.